New Customers Get 10% Off – Use Code: LUX10

Secretagogue Peptide

CJC No DAC/Iipamorelin

5.0 Reviews

CJC/Ipa BlendMod GRF 1-29 + IpamorelinModified GRF + Ipamorelin

A carefully crafted peptide combination designed to boost growth hormone release by simultaneously activating GHRH and ghrelin receptors in experimental research models. Premium Research Peptide.

Original price was: $79.99.Current price is: $71.99.

2 Day FAST Shipping

99%+ Purity Tests

Ships from USA

USA Lab Tested

We accept :

Certificate of Analysis

Third Party Tested by Freedom Diagnostics

How CJC No DAC/Iipamorelin Works

The Science, Simplified

Dual-Pathway Receptor Synergy

This blend combines two complementary secretagogues. CJC-1295 (No DAC) is a GHRH analog that targets the GHRH receptor, while Ipamorelin is a selective ghrelin receptor agonist.
Key insight: When used together, research shows a “synergy factor” of approximately 2.7x. While GHRH alone might produce a 20-fold GH increase, the combination has been observed to yield up to a 54-fold increase by activating the pituitary from two different angles simultaneously.
GE
Primary

Gene Expression

Epigenetic Modulation

Upregulates 59% of affected genes Activates 47 DNA repair genes Suppresses inflammatory pathways

COL
Strongest

Gene Expression

Epigenetic Modulation

Upregulates 59% of affected genes Activates 47 DNA repair genes Suppresses inflammatory pathways

Cu²⁺
Supportive

Gene Expression

Epigenetic Modulation

Upregulates 59% of affected genes Activates 47 DNA repair genes Suppresses inflammatory pathways

Preservation of Pulsatile GH Patterns

The "No DAC" (Drug Affinity Complex) version of CJC-1295 has a shorter half-life (30 minutes to 2 hours) compared to DAC versions.

Key insight: This allows the body to maintain its natural, pulsatile growth hormone release pattern rather than a constant “bleed.” In research, this is considered more physiological and reduces the risk of pituitary desensitization or “GH bleed.”

Selective Ipamorelin Signaling

Ipamorelin is the first truly selective GH secretagogue. Unlike older GHRPs (like GHRP-2 or GHRP-6), it does not significantly activate the receptors responsible for cortisol or prolactin release.

Key insight: Research indicates that Ipamorelin amplifies the GH pulse without the common side effects of increased appetite, water retention, or stress hormone elevation, making it a highly precise tool for metabolic studies.

Wrinkle Reduction Comparison

Safety Profile from Research

What clinical studies report

This blend is noted for its high tolerability in clinical trials, largely due to the selectivity of Ipamorelin and the physiological nature of the "No DAC" CJC-1295.

🧿 Common Digestive Issues

20%

Injection Site Reaction

mild

15%

Flushing/Warmth

mild

12%

Headache

mild

Safety Advantage

High Selectivity

  • Zero Cortisol Spike: Ipamorelin does not elevate ACTH or cortisol, preserving the subject's natural stress response.
  • Prolactin Neutrality: Clinical data shows no significant impact on prolactin levels, eliminating the risk of gynecomastia in research models.
  • Reversibility: Because the "No DAC" formulation clears the system quickly, any observed effects or side effects are rapidly reversible upon cessation of the protocol.

📊 Discontinuation Rates

🚫 Trial Exclusions

⚡ Regulatory Status

💡 Researcher Notes

Compound Information

Technical specifications for each component

🔬 Molecular Profile

GHRH Analog Component

Other names

Mod GRF 1-29, Modified GRF

Type

GHRH analog

Amino Acids

29

Molecular Weight

~3,367 g/mol

Mechanism

GHRH receptor agonist

Half-life (No DAC)

30 min - 2 hours

PubChem Databases

🧊 Storage Requirements

Selective GHRP Component

This combination is designed to support synergistic growth hormone release through dual-pathway activation while helping preserve a natural pulsatile secretion pattern.

Type

Growth hormone secretagogue

Amino Acids

5 (pentapeptide)

Molecular Weight

711.85 g/mol

Sequence

Aib-His-D-2-Nal-D-Phe-Lys-NH2

Mechanism

Ghrelin receptor (GHSR-1a) agonist

Selectivity

No cortisol/prolactin elevation

📋 Blend Information

Why This Combination

This combination is designed to support synergistic growth hormone release through dual-pathway activation while helping preserve a natural pulsatile secretion pattern.

Typical ratio

1:1 by weight

Combined half-life

1-2 hours (functional)

Synergy factor

~2.7× vs single pathway

Route

Subcutaneous injection

Raun et al., 1998

Frequently Asked Questions

Common questions about CJC No DAC/Iipamorelin

DAC stands for Drug Affinity Complex, which extends the half-life of CJC-1295 to several days. The "No DAC" version (also called Mod GRF 1-29) has a shorter half-life, which mimics the body’s natural pulsatile release of growth hormone. This is generally preferred in research to avoid over-stimulating the pituitary gland.
They work on different receptors. CJC-1295 acts as a "gas pedal" to start GH production, while Ipamorelin acts as a "brake-releaser" (by inhibiting somatostatin) and an amplifier. Together, they create a much stronger GH pulse than either could achieve on its own.
No. Unlike GHRP-6, which strongly activates the ghrelin receptors in the stomach that trigger hunger, Ipamorelin is highly selective for the pituitary receptors. Research subjects typically do not report the intense "ghrelin hunger" associated with older peptides.
The lyophilized powder is reconstituted with Bacteriostatic Water. Because it contains two different peptides, it is important to swirl the vial very gently to ensure a homogenous solution without damaging the delicate peptide structures.
No. While the individual components have been through various stages of clinical trials, the blend is currently classified as an investigational research compound. it is not approved for human use and is sold strictly for laboratory evaluation.

Sources & References

Peer-reviewed research

Journal of Clinical Endocrinology & Metabolism

Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I Secretion by CJC-1295, a Long-Acting Analog of GH-Releasing Hormone, in Healthy Adults

2006

Teichman SL, Neale A, Lawrence B et al.

View Source

European Journal of Endocrinology

Ipamorelin, the first selective growth hormone secretagogue

1998

Raun K, Hansen BS, Johansen NL et al.

View Source

Journal of Clinical Endocrinology & Metabolism

On the actions of the growth hormone-releasing hexapeptide, GHRP

1991

Bowers CY, Reynolds GA, Durham D et al.

View Source

Translational Andrology and Urology

A Review of Growth Hormone Secretagogues

2018

Sigalos JT, Pastuszak AW

View Source

Translational Andrology and Urology

A Review of Growth Hormone Secretagogues

2018

Sigalos JT, Pastuszak AW

View Source
  • Important Research Notice

Not for human consumption. This product is sold exclusively for research and educational purposes. It is not intended to diagnose, treat, cure, or prevent any disease.

All clinical trial data and research findings presented on this page are sourced from peer-reviewed journals and official publications. They are provided for educational reference only and should not be interpreted as medical advice or product claims.

By purchasing this product, you confirm that you are a qualified researcher and will use it in accordance with all applicable laws and regulations.

My Account
Follow Us
Linkedin X-twitter Icon-instagram-1 Facebook-square